经肝动脉化疗栓塞术联合阿帕替尼对中晚期原发性肝癌患者血清甲胎蛋白异质体的影响

Effect of Transcatheter Arterial Chemoembolization Combined with Apatinib on Serum Alpha-Fetoprotein Heterogeneity in Patients with Advanced Primary Liver Cancer

目的:分析肝动脉化疗栓塞术联合阿帕替尼对中晚期原发性肝癌患者血清甲胎蛋白异质体的影响。方法:将符合标准的83例中晚期原发性肝癌患者随机分组,对照组41例予肝动脉化疗栓塞术,观察组42例予肝动脉化疗栓塞术联合阿帕替尼治疗,治疗3个月后,对比2组治疗前后血清甲胎蛋白异质体的变化。结果:观察组患者肿瘤直径、AFP、AFP-L3、ALT水平均明显低于对照组,毒副反应发生率、复发率低于对照组,差异具有统计学意义(P<0.05)。结论:肝动脉化疗栓塞术联合阿帕替尼治疗中晚期原发性肝癌患者不仅可有效缩小肿瘤直径,改善肝功能,还可减少患者毒副反应及复发概率,疗效显著,安全性高,值得临床推广。

Objective:To analyze the effect of transcatheter arterial chemoembolization combined with apatinib on serum alpha-fetoprotein heterogeneity in patients with advanced primary liver cancer.Methods:83 patients with advanced hepatocellular carcinoma were randomly divided into the control group.41 patients in the control group were treated with transcatheter arterial chemoembolization.42 patients in the observation group were treated with transcatheter arterial chemoembolization combined with apatinib.Changes in protein heterogeneity.Results:The tumor diameter,AFP,AFP-L3 and ALT levels in the observation group were significantly lower than those in the control group.The incidence of toxic side effects and recurrence rate were lower than those in the control group(P<0.05).Conclusions:Transcatheter arterial chemoembolization combined with apatinib in the treatment of patients with advanced primary liver cancer can not only effectively reduce the tumor diameter,improve liver function,but also reduce the risk of side effects and recurrence of patients,with remarkable curative effect and high safety.Promotion.